We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie’s Humira Approved in EU for Severe Chronic Plaque Psoriasis in Children, Teens
AbbVie’s Humira Approved in EU for Severe Chronic Plaque Psoriasis in Children, Teens
The European Medicines Agency has greenlighted AbbVie’s Humira for the treatment of severe chronic plaque psoriasis in children and adolescents who have had an inadequate response to or are poor candidates for topical and photo therapies.